---
title: "Viemed Healthcare | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 75.41 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285268042.md"
datetime: "2026-05-05T21:03:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285268042.md)
  - [en](https://longbridge.com/en/news/285268042.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285268042.md)
---

# Viemed Healthcare | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 75.41 M

Revenue: As of FY2026 Q1, the actual value is USD 75.41 M, beating the estimate of USD 74.4 M.

EPS: As of FY2026 Q1, the actual value is USD 0.06, missing the estimate of USD 0.09.

EBIT: As of FY2026 Q1, the actual value is USD 4.601 M.

#### Revenue

-   Viemed Healthcare, Inc. reported total revenue of $75,414 thousand for Q1 2026, marking a 28% year-over-year increase from $59,129 thousand in Q1 2025.
-   Ventilators, non-invasive & invasive rental revenue was $35,360 thousand in Q1 2026, up from $32,159 thousand in Q1 2025, representing 46.9% of total revenue in Q1 2026 compared to 54.4% in Q1 2025.
-   Other home medical equipment rentals revenue increased to $16,198 thousand in Q1 2026 from $12,962 thousand in Q1 2025, accounting for 21.5% of total revenue in Q1 2026, which was unchanged from 21.9% in Q1 2025.
-   Equipment and supply sales revenue significantly rose to $17,488 thousand in Q1 2026 from $7,519 thousand in Q1 2025, representing 23.2% of total revenue in Q1 2026, up from 12.7% in Q1 2025.
-   Service revenues were $6,368 thousand in Q1 2026, a decrease from $6,489 thousand in Q1 2025, and represented 8.4% of total revenue in Q1 2026, down from 11.0% in Q1 2025.

#### Operational Metrics

-   Gross profit for Q1 2026 was $42,827 thousand, reflecting a 57% gross profit margin, compared to $33,279 thousand and a 56% gross profit margin in Q1 2025.
-   Net income attributable to Viemed Healthcare, Inc. was $2,582 thousand in Q1 2026, slightly lower than $2,625 thousand in Q1 2025.
-   Adjusted EBITDA grew 12% year-over-year to $14,311 thousand in Q1 2026, up from $12,765 thousand in Q1 2025.
-   Total assets as of March 31, 2026, amounted to $197,361 thousand.
-   Working capital as of March 31, 2026, was $9,105 thousand.
-   Long term debt as of March 31, 2026, stood at $8,334 thousand.

#### Cash Flow

-   Operating cash flow generated was $8,071 thousand for Q1 2026.
-   Free cash flow for Q1 2026 was $2,586 thousand.
-   Net capital expenditures (Net CAPEX) for Q1 2026 were - $5,485 thousand.
-   Trailing twelve months (TTM) free cash flow was $36,344 thousand as of March 31, 2026.

#### Unique Metrics

-   Sleep platform patients increased by 57% year-over-year, with new patient starts rising by 42%.
-   Ventilator patient growth remained stable at 2% year-over-year, reaching 12,089 patients in Q1 2026.
-   PAP Therapy Patients increased to 35,938 in Q1 2026 from 22,899 in Q1 2025, while Sleep Resupply Patients grew to 33,661 in Q1 2026 from 22,941 in Q1 2025.
-   The company repurchased 150,000 shares for $1.4 million and reduced debt by $3.2 million through term loan repayments.
-   As of March 31, 2026, Viemed Healthcare, Inc. had $46 million in unfunded commitments available under existing credit facilities.

#### Outlook / Guidance

-   For the full year 2026, Viemed Healthcare, Inc. narrowed and raised its net revenue guidance to $312 million to $320 million, and reaffirmed its Adjusted EBITDA guidance at $65 million to $69 million.
-   Net capital expenditures are now projected to be 9% to 10.5% of net revenue, an update from the previous range of 10% to 11.5%.

### Related Stocks

- [VMD.US](https://longbridge.com/en/quote/VMD.US.md)

## Related News & Research

- [VMD Sciences Expands Veterinary Pharmaceutical Supply Solutions to Address Drug Shortages and Emerging Disease Threats in the United States](https://longbridge.com/en/news/287125444.md)
- [Viemed Healthcare Q1 revenue rises 28%, raises outlook](https://longbridge.com/en/news/285269464.md)
- [West Pharma amends 8-K on material cyberattack disclosure](https://longbridge.com/en/news/287111623.md)
- [Abundia Global Impact amends 8-K to disclose 2025 equity plan share increase](https://longbridge.com/en/news/287111321.md)
- [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md)